BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion, trauma and osteoporosis markets, today has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.
“We are very encouraged by the results of our Pilot animal study and look forward to commencing our Pivotal animal study by mid-2018 and presenting results at future scientific conferences,” said Steve La Neve, chief executive officer of Bone Biologics.
“In its first clinically relevant sheep study, rhNELL-1 demonstrated increases in fusion and quantity of bone compared to the control,” said Dr. Bill Walsh, professor and director, Surgical and Orthopedic Research Laboratories (SORL).
“We look forward to completing ongoing activities to advance into clinical trials in 2019,” stated La Neve.
About Bone Biologics
Bone Biologics (OTC QB: BBLG) is pursuing regenerative medicine for bone including undertaking groundbreaking work and building on unprecedented research on the NELL-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific literature.
Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. NELL-1 is a recombinant human protein growth factor that is essential for normal bone development.
For more information, please visit the company's website at www.bonebiologics.com.